Studies Show Mild Hyperthermia Enhances Antitumor Effects of,Alfacell's Onconase ( BLOOMFIELD N.J. March 22 2007 /PRNe...)

Studies Show Mild Hyperthermia Enhances Antitumor Effects of,Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today reported that in vitro studies show mild hyperthermia enhances the therapeutic effects of ONCONASE (ranpirnase), the company's lead investigational drug candidate.

In a paper entitled, "Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with ONCONASE," published in the International Journal of Oncology (April 2007), the studies conducted by Zbigniew Darzynkiewicz, M.D., Ph.D., and collaborators demonstrated apoptosis, or programmed cell death, increased up to 200 percent when ONCONASE was applied to lymphoblastoid TK6 cells at 40 degrees Celsius (104 degrees Fahrenheit) compared to treatment at 37.5 degrees Celsius (99.5 degrees Fahrenheit). In these experiments, apoptosis was manifested by classical changes in cell morphology and the activation of caspase-3, both considered hallmarks of the apoptotic mode of cell death.

"This is very encouraging data that support our work in investigating multiple therapeutic options for the ONCONASE franchise," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "These studies indicate that we may be able to increase the drug's effectiveness in combination with mild hyperthermia. This opens up new possibilities in creating treatment regimens for various indications."

Whole body hyperthermia at 40 degrees Celsius (104 degrees Fahrenheit) is considered to be a safe therapy that does not lead to any serious or sustained organ dysfunction, and is used in the treatment of cancer, either alone or in combination with chemotherapy or radiotherapy.

To view the paper on-line, please visit http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abst ractPlus&list_uids=17332922&que
'"/>

Page: 1 2 3
Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

Post Your Comments:

(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue: ... Optical Coherence Tomography (OCT) ... OBJECTIVES BCC,s ... offer synopsis of the current and future ...

(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...

(Date:5/21/2013)... 21, 2013 Healthcare organizations expanding into emerging markets ... , India and ... no shortcuts. This is proving particularly challenging, considering the ... must change the dialogue around BRIC, as it is ... and building regional partnerships to build a sustainable business. ...

Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2 Global Markets and Technologies for Optical Coherence Tomography (OCT) 3 Global Markets and Technologies for Optical Coherence Tomography (OCT) 4 Global Markets and Technologies for Optical Coherence Tomography (OCT) 5 Global Markets and Technologies for Optical Coherence Tomography (OCT) 6 Global Markets and Technologies for Optical Coherence Tomography (OCT) 7 Global Markets and Technologies for Optical Coherence Tomography (OCT) 8 Global Markets and Technologies for Optical Coherence Tomography (OCT) 9 Global Markets and Technologies for Optical Coherence Tomography (OCT) 10 Global Markets and Technologies for Optical Coherence Tomography (OCT) 11 Global Markets and Technologies for Optical Coherence Tomography (OCT) 12 Global Markets and Technologies for Optical Coherence Tomography (OCT) 13 Global Markets and Technologies for Optical Coherence Tomography (OCT) 14 Global Markets and Technologies for Optical Coherence Tomography (OCT) 15 Global Markets and Technologies for Optical Coherence Tomography (OCT) 16 Global Markets and Technologies for Optical Coherence Tomography (OCT) 17 Global Markets and Technologies for Optical Coherence Tomography (OCT) 18 Global Markets and Technologies for Optical Coherence Tomography (OCT) 19 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7 Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2 Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3 Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4

[0] Global Markets and Technologies for Optical Coherence Tomography (OCT)[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine [0] Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets

... NEW YORK, Sept. 28 Delcath Systems, Inc. (Nasdaq: ... the William Blair Emerging Growth Stock Conference on Tuesday, October ... Mr. David McDonald, Chief Financial Officer, will provide an overview ... Attendance at this conference is by invitation only. Delcath ...

... BOTHELL, Wash., Sept. 27 SCOLR Pharma, Inc. (NYSE ... Johnson has been appointed as the Chairman of its ... remain a member of the Board. ... of Matrixx Initiatives, Inc. Under Johnson,s leadership, Matrixx successfully ...

Cached Medicine Technology:Delcath to Present at the William Blair Emerging Growth Stock Conference 2 SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 2 SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 3

Delcath to Present at the William Blair Emerging Growth Stock Conference SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director

(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and ... free Community Wellness Fair to educate the public on health ... held on Wednesday, May 22, 2013 from 4:00 pm until ... Old Mallard Creek Road, Charlotte, NC 29262). , ... the Mecklenburg County Department of Social Services are ...

(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...

(Date:5/21/2013)... 2013 Diversity Focus, a non-profit organization ... all residents in the Creative Corridor region, is releasing ... a news conference on Thursday, May 23rd at 10:30 ... in 2008. , The survey is a ... support efforts that attract, nurture and retain people of ...

(Date:5/21/2013)... two proteins, thrombospondin-1 and prosaposin, play in discouraging ... a five-amino acid fragment of prosaposin that significantly ... breast and lung cancer. The findings suggest that ... a variety of cancers. , The study ... Children,s Hospital, Vivek Mittal, PhD, at Weill Cornell ...

(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Vinci surgery robot lawsuit is nearing its conclusion ... According to Bloomberg.com, during closing statements yesterday, an attorney ... dealership, alleging the company wanted to tie sales and ... do all the training to keep control of surgeons, ...

Breaking Medicine News(10 mins):Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4 Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Changing cancer's environment to halt its spread 2 Health News:Changing cancer's environment to halt its spread 3 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3 Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4

[0] Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives [0] ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors [0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Changing cancer's environment to halt its spread [0] Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial

... , ROCHESTER, N.Y., Aug. 12 VirtualScopics, Inc. (Nasdaq: ... announced its financial results for the quarter and six months ended June 30, ... Revenues for the second quarter of 2009 increased 47% to $2.5 ... Gross profit for the second quarter of 2009 increased 96% ...

... NEWARK, N.J., Aug. 12 BioNeutral Group, Inc. ("BioNeutral") (OTC ... that ATS Labs using the EPA required AOAC Sporicidal Test with Ygiene(TM) ... over one million live Clostridium ... time frame - performance which is up to 75 times faster than ...

... With the recent increase in the tobacco tax, many Floridians ... times - do they pay the extra dollar per pack or ... The Florida Quitline (1-877-U-CAN-NOW) is here to help by offering free ... According to Kim Berfield, Deputy Secretary of the Florida Department of ...

... , , , , ... a leading provider of Linux-bas e d ... Systems, a national health care management company, has deployed Arkeia Network Backup. ... Goold has realized dramatic improvements in backup performance and in backup administration. ...

... August 12 Fountain Healthy Aging,Inc. announced on August 12 ... Partners and Oak Resources Limited which provides the Company,with a ... the,agreement, Fountain has the right to draw down from the ... a term of 24 months. The,first tranche investment of $1,000,000 ...

... , WESTFIELD, Ind., Aug. 12 ... company for healthcare providers, announced the successful "Stage 6" designation ... hospital located in Silver City, New Mexico. maxIT assisted the ... IT consultants to support the implementation of several HIS modules. ...

VirtualScopics, Inc. Reports a Record Breaking Quarter BioNeutral's Ygiene(TM) Achieves World's Fastest Kill Time With a 100% Total Spore Eradication Verified In Independent Sporicidal/Sterilant Test The Time To Quit Is Now -- Free NRT Is Available Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition

Custom Pediatric Nebulizer Assembly W/Tubing...

... Patients over the age of 3 can choose ... STAR®. The same design principle applies to both:, ... and minimize aerosol output when the patient exhales ... optimum size to leave the nebulizer. The result ...

... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...

... Portex® medication nebulizers offer a spill-proof design ... to a 45° angle. All medical nebulizers ... wide variety of configurations are available., ... , ,Portex® medication nebulizers feature consistently ...

Medicine Products:

Pediatric Custom Nebulizers PARI LC STAR® Reusable Nebulizer Raindrop® Medication Nebulizer - Pediatric Aerosol Mask & Tubing 007767 Medication Nebulizer Kit